Bone-Targeted Platinum Nanoframework Prevents Postmenopausal Osteoporosis via Transmembrane Protein 16A Channel Blockade and Reactive Oxygen Species Scavenging

) excretion and effectively inhibiting the activation of the RANKL-RANK pathway, and attenuates osteoclast activity. Concurrently, the inherent antioxidant properties of both Pt NF and TF scavenge a broad spectrum of ROS, alleviating the ROS-enriched POP microenvironment and further inhibiting osteoclast differentiation. In vivo experimental results have confirmed that TF@Pt-Aln can enhance the trabecular bone mass and microarchitecture by inhibiting abnormal bone resorption, thereby reversing the progression of osteoporosis in ovariectomized (OVX) mouse models. Furthermore, TF@Pt-Aln exhibits excellent biocompatibility and reduces the risk of osteonecrosis of the jaw, rendering it a promising candidate for the clinical treatment of POP.